Low-dose Aspirin Therapy for Esophageal Cancer

Low-dose Aspirin Therapy for Stage II-III Esophageal Cancer- A Multi-Center, Open Label, Randomized Controlled Phase III Trial

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02326779

Enrollment

Registered

2014-12-29

Start date

2016-03-31

Completion date

2018-12-31

Last updated

2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Keywords

esophageal cancer, aspirin, survival

Brief summary

The aim of this study is to evaluate the survival benefit of low-dose aspirin use for stage II-III esophageal cancer patients.

Detailed description

The investigators aimed to evaluate the hypothesis that low-dose aspirin can improve survival in stage II-III esophageal cancer patients, and to evaluate whether this effect is influenced by PIK3CA, KRAS, BRAF mutation and COX-2 expression. Eligible participants will be randomized to either aspirin treatment arm (100 mg aspirin OD for 3 years), or non-aspirin user arm in 1:1 ratio. After randomization, participants will receive 3 monthly assessments during treatment and follow-up.

Interventions

DRUGAcetylsalicylic acid

Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male or female subjects with an age of 18 years or older. 2. Subjects with Stage II-III histological proven esophageal cancer. 3. Subjects with performance status (PS) of 0-1 or ECOG performance status 0-2. 4. Subjects must have signed an approved informed consent prior to any study procedures. 5. Subjects with adequate bone marrow, hepatic and renal functions, with a) neutrophils ≥ 1.5x109/ L; platelets ≥ 100x109/L; hemoglobin ≥ 9g/dL; b) Total bilirubin ≤ 2.0 x the upper limit normal; ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastasis); c) creatinine clearance \> 50 ml/min; 6. Subjects undergone complete resection of primary tumor; 7. Subjects with life expectancy ≥ 3 months. 8. Completed standard therapy ( at least 3 months of chemotherapy ± radiotherapy ) 9. Within 120 days of completion of standard therapy (surgery, chemotherapy ± radiotherapy)

Exclusion criteria

1. Subjects with haemorrhagic diathesis (i.e. haemophilia). 2. Subjects with prior malignant tumors except for esophageal cancers in the past 5 years. 3. Subjects with documented or suspected central nervous system metastases. 4. Subjects with serious, nonhealing wound, ulcer, or bone fracture. 5. Subjects with a history of stroke, coronary arterial disease, angina, or vascular disease. 6. Subjects who are pregnant, lactating, or not using adequate contraception. 7. Subjects who have known allergy to NSAID or Aspirin. 8. Subjects receiving other antiplatelet agents (i.e. clopidogrel, ticlopidine) or anticoagulants (i.e. warfarin, low molecular weight heparins). 9. Subjects receiving current long term treatment (≥ 1 month) with Aspirin or other NSAIDs. 10. Subject unwilling or unable to comply with study requirements.

Design outcomes

Primary

Measure	Time frame
Disease-free survival	5 years
Overall survival	5 years

Secondary

Measure	Time frame
Adverse events	5 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026